These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16458385

  • 1. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 2. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Aug; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 3. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
    Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I, Van Gaal L.
    Horm Metab Res; 2001 Oct; 33(10):602-7. PubMed ID: 11607880
    [Abstract] [Full Text] [Related]

  • 4. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 5. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 6. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [Abstract] [Full Text] [Related]

  • 7. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 8. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
    He G, Andersen O, Haugaard SB, Lihn AS, Pedersen SB, Madsbad S, Richelsen B.
    Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, Wagner OF, Huber K, Waldhäusl W, Pacini G, Kautzky-Willer A.
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [Abstract] [Full Text] [Related]

  • 10. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 May; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 11. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T, Proidl S, Knöbl P, Teufelsbauer H, Schnack C, Schernthaner G.
    Thromb Haemost; 1992 Sep 07; 68(3):253-6. PubMed ID: 1440487
    [Abstract] [Full Text] [Related]

  • 12. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB.
    Clin Endocrinol (Oxf); 2006 Apr 07; 64(4):444-9. PubMed ID: 16584518
    [Abstract] [Full Text] [Related]

  • 13. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM, Barrow BA, Grant PJ, Levy JC.
    Diabetologia; 2002 May 07; 45(5):635-41. PubMed ID: 12107743
    [Abstract] [Full Text] [Related]

  • 14. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 May 07; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 15. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 May 07; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 16. Correlation between omental TNF-alpha protein and plasma PAI-1 in obesity subjects.
    Cao YL, Wang YX, Wang DF, Meng X, Zhang J.
    Int J Cardiol; 2008 Aug 29; 128(3):399-405. PubMed ID: 17698217
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb 29; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 18. Food deprivation induces adipose plasminogen activator inhibitor-1 (PAI-1) expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice.
    Oishi K, Ohkura N, Matsuda J, Ishida N.
    Thromb Haemost; 2007 Oct 29; 98(4):864-70. PubMed ID: 17938813
    [Abstract] [Full Text] [Related]

  • 19. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
    Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF.
    Thromb Haemost; 2005 Dec 29; 94(6):1190-5. PubMed ID: 16411393
    [Abstract] [Full Text] [Related]

  • 20. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
    Morimitsu LK, Fusaro AS, Sanchez VH, Hagemann CC, Bertini AM, Dib SA.
    Diabetes Res Clin Pract; 2007 Dec 29; 78(3):340-8. PubMed ID: 17544539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.